Selank Dosage: Cognitive Research Protocol

Read this first

Dosage and protocol figures on this page are reproduced only from the matching PeptideDosages.com protocol. The 3 ml table is arithmetic based on those source amounts and the listed vial sizes. Educational research only — not instructions or medical advice.

Dosage chart

The dosage amounts and schedules below come only from PeptideDosages.com. Syringe-unit figures are mathematical conversions of those source amounts using exactly 3 ml of bacteriostatic water. Educational reference only — not instructions or medical advice.

Selank · 10 mg Vial

This Selank dosage chart explains how

Primary human research route: Intranasal drops or measured intranasal solution.
5 mL final volume: 2 mg/mL, 200 mcg per verified 0.10 mL spray, and 50 nominal sprays.
10 mL final volume: 1 mg/mL, 100 mcg per verified 0.10 mL spray, and 100 nominal sprays.
Device check: Confirm the pump output and follow its priming instructions before using the calculation.
Research context: Human studies used different amounts, durations, and manufactured drop formulations.

# Mathematical Actuator Equivalents

Measured Final Volume	Vehicle Added After Transfer	Final Concentration	Per Verified 0.10 mL Spray
5.0 mL	About 2.0 mL	2,000 mcg/mL	200 mcg<br>50 nominal sprays
10.0 mL	About 7.0 mL	1,000 mcg/mL	100 mcg<br>100 nominal sprays

Source chart on peptidedosages.com

Other cognitive compounds

SemaxACTH(4-10) analogue heptapeptide Semax + SelankACTH(4-10) analogue + tuftsin analogue blend CerebrolysinPorcine brain-derived peptide preparation CortagenSynthetic tetrapeptide bioregulator (cortex-derived sequence)DihexaAngiotensin IV analogue, HGF/c-Met potentiator DSIPNonapeptide

All research protocols

Selank: research background

What the compound is

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) that is a derivative of the endogenous peptide tuftsin (PMID 18661785). It is considered a neuroactive peptide (PMID 41490200).

How it is thought to work

Selank has anxiolytic and psychostimulant effects, and its neurobiochemical actions include activating brain monoaminergic systems, increasing dopamine synthesis and turnover, and modulating tyrosine hydroxylase activity (PMID 18661785). It has been hypothesized that Selank's effects may involve the GABAergic system, potentially affecting the interaction of GABA with GABAA receptors (PMID 28293190). In cell studies, Selank alone did not change the mRNA levels of GABAergic system genes in neuroblastoma IMR-32 cells, but it influenced gene expression when combined with GABA or olanzapine, suggesting it might enhance the effect of other compounds on these genes (PMID 28293190). In orthopedics-focused reviews, Selank is noted for potentially enhancing brain-derived neurotrophic factor and HGF/c-Met pathways, which are important for neuroplasticity (PMID 41490200).

What laboratory and animal studies report

In rat studies, Selank restored cognitive processes that were impaired by chronic inhibition of the cerebral catecholaminergic system (PMID 18683497). Selank in rats reduced specific symptoms of depression, such as increased immobility in forced swimming and decreased sucrose intake, particularly in genetically-based models of depression (PMID 18661785). In rats, a single injection of Selank attenuated aversive signs of morphine withdrawal, including convulsive reactions, ptosis, and posture disorders, and increased tactile sensitivity (PMID 36322304). Selank administration in rats exposed to chronic restraint stress led to decreased corticosterone levels, reduced stress-related morphological changes in the large intestine (PMID 32651826), and helped restore intestinal microbiota disruptions caused by stress (PMID 31236882).

Human evidence so far

Clinical studies have shown that Selank has an anxiolytic effect comparable to that of classical benzodiazepine drugs (PMID 28293190). In a study with 52 healthy human participants, Selank was investigated for its effects on whole-brain resting-state functional connectivity (FC). It showed specific effects on FC between the right amygdala and the right temporal cortex (PMID 32342318).

Open questions and limitations

While preclinical studies involving therapeutic peptides like Selank show promise, there is a recognized current lack of clinical trials (PMID 41490200). Selank has completed the third phase of clinical testing as a selective anxiolytic (PMID 18661785).

Key terms explained

Anxiolytic: A substance that reduces anxiety. GABAergic system: Refers to the system involving gamma-aminobutyric acid (GABA), a primary inhibitory neurotransmitter in the central nervous system. Functional connectivity (FC): Refers to the temporal correlations between spatially remote neurophysiological events, indicating how different brain regions communicate. Amygdala: A brain region involved in emotion processing, particularly fear and anxiety. Dorsolateral prefrontal cortex (DLPFC): A brain region involved in executive functions, such as working memory. Neuroplasticity: The brain's ability to reorganize itself by forming new neural connections throughout life.

Studies cited in this section

Functional Connectomic Approach to Studying Selank and Semax Effects. — Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 2020 (PMID 32342318)
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. — Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews, 2026 (PMID 41490200)
Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats. — Bulletin of experimental biology and medicine, 2022 (PMID 36322304)
GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. — Frontiers in pharmacology, 2017 (PMID 28293190)
Morphological Changes in the Large Intestine of Rats Subjected to Chronic Restraint Stress and Treated with Selank. — Bulletin of experimental biology and medicine, 2020 (PMID 32651826)
State of Colon Microbiota in Rats during Chronic Restraint Stress and Selank Treatment. — Bulletin of experimental biology and medicine, 2019 (PMID 31236882)
[Effects of heptapeptide selank on genetically-based and situation-provoked symptoms of depression in behavior in WAG/Rij and Wistar rats, and in BALB/c mice]. — Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova, 2008 (PMID 18661785)
Effect of selank on cognitive processes after damage inflicted to the cerebral catecholamine system during early ontogeny. — Bulletin of experimental biology and medicine, 2007 (PMID 18683497)

Summarised from the PubMed abstracts listed above. Educational reference only — not medical advice or instructions.

Nearby in the protocol A–Z

Continue your research

Three steps most readers take from here

View verified suppliers

1 · Read the background
Mechanism, half-life and what the published Selank literature actually shows.
Selank research brief
2 · Plan the bench work
Work out reconstitution volumes and concentrations before ordering anything, so you buy the vial size your protocol actually needs.
Reconstitution calculator
3 · Check the paperwork
Only use material released with a lot-matched third-party certificate of analysis. Suppliers we have checked publish theirs openly.
Selank reference page How we verify suppliers

We are an independent publication: we sell nothing, hold no stock and take no payment. Outbound supplier links are marked nofollow/sponsored. Compounds discussed are laboratory research reagents, not medicines.

Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.

Selank dosage protocol